WuXi AppTec pitches integrated CRDMO for global drug manufacturing

By AI, Created 9:00 AM UTC, May 20, 2026, /AGP/ – WuXi AppTec is positioning its integrated CRDMO platform as a way to speed drug development and manufacturing across Asia, Europe and North America. The company says its global network, quality system and newer technologies are aimed at helping biotech and pharma clients move complex therapies into commercial supply.

Why it matters: - WuXi AppTec is framing integrated CRDMO services as a way to cut handoffs across discovery, development and manufacturing. - The model is designed to help biotech and pharmaceutical companies move therapies from concept to patient delivery faster. - The company says global manufacturing capacity matters most for peptides, oligonucleotides and other complex modalities that need scalable, regulated supply.

What happened: - WuXi AppTec outlined its CRDMO platform as a global drug manufacturing option for biotech and pharmaceutical clients. - The company said its network spans innovation hubs in Asia, Europe and North America. - The platform combines drug discovery, development and manufacturing within one connected system. - The company highlighted commercial and clinical manufacturing sites in Switzerland, the United States, Singapore, and China.

The details: - In Couvet, Switzerland, WuXi AppTec provides oral solid dosage manufacturing, packaging and labeling for commercial drug products supplied to the United States, European Union, United Kingdom, Japan, Canada, Australia, New Zealand and China. - Couvet has expanded capacity and a new PSD-4 spray dryer. - The Middletown, Del., site is expected to add oral solid dosage manufacturing, packaging, labeling, distribution, analytical development, quality control testing and sterile fill-finish services for vials, cartridges and prefilled syringes. - Middletown will support peptide and oligonucleotide drug products. - The San Diego site serves as a hub connecting API manufacturing with clinical drug product for clinical supply. - Taixing operates 12 manufacturing plants, with additional expansion planned for small molecules, peptides, oligonucleotides and PMO production. - A new Singapore site will add global API manufacturing capacity. - The Wuxi site provides sterile injectable formulation and manufacturing with annual capacity above 100 million units across liquid and lyophilized vials, prefilled syringes and cartridges. - WuXi AppTec said the integrated network helped move a Phase 3 drug through scale-up in Couvet in five months, supporting a New Drug Application filing and product approval on time. - The company uses flow chemistry and biocatalysis to improve reaction control, safety and scale-up. - For peptides, WuXi AppTec combines solid-phase peptide synthesis and liquid-phase peptide synthesis to improve efficiency and scalability for longer sequences. - Tangential flow filtration, continuous flow chromatography and spray drying support purification and API isolation. - For oligonucleotides, the company uses thin film evaporation, continuous flow chromatography and biocatalytic fragment ligation. - WuXi AppTec supports oral and parenteral peptide drug products from preclinical to commercial stages. - The company says it supports 70+ preclinical and 10+ clinical oral peptide programs. - WuXi AppTec also supports lipid nanoparticle delivery technologies for oligonucleotides. - Expanded spray drying capacity in China and Switzerland is meant to address delivery and bioavailability for complex modality therapies. - The company said its One Global Quality System keeps quality standards consistent across sites in Asia, Europe and North America. - Global computerized systems replace paper-based processes and standardize documentation and oversight. - Standardized GMP procedures and training support shared requirements across the network. - Couvet uses the same global procedures, digital systems and training as other WuXi AppTec sites. - Inspections by Swissmedic, the U.S. Food and Drug Administration and ANVISA were completed without interrupting production. - The same quality framework is being applied to Middletown and Singapore. - WuXi AppTec said it hosts hundreds of client audits each year with a transparent approach.

Between the lines: - The message is broader than site listings: WuXi AppTec is selling network integration as the main advantage. - Faster transfers, fewer duplicate audits and common quality systems can reduce friction for clients moving programs across regions. - The company is also signaling that complex modalities are a growth focus, not just traditional small-molecule manufacturing.

What’s next: - WuXi AppTec is continuing to invest in global capabilities and capacity. - Middletown and Singapore appear to be the next sites expected to deepen the company’s U.S. and Asia footprint. - The company says the quality system framework will continue to support IND filings, marketing applications and commercial readiness.